Published: Jan. 1, 2024
Language: Английский
Frontiers in Aging Neuroscience, Journal Year: 2025, Volume and Issue: 16
Published: Jan. 29, 2025
Objective The aim of this study was to compare the efficacy and safety anti-tau protein monoclonal antibodies for Alzheimer’s disease (AD). Tau aggregation, a key pathological feature AD, is closely associated with neurodegeneration cognitive decline. Targeting tau has emerged as promising therapeutic strategy. By investigating effects on function, progression, overall quality life in patients which can provide valuable insights into their potential option devastating neurodegenerative disorder. Methods randomized controlled trials (RCTs) Gosuranemab, Semorinemab, Tilavonemab, Zagotenemab (AD) were systematically searched across PubMed, Embase, Web Science Cochrane Library, up May 2024. control group included placebo. indicators change Mini Mental State Examination (MMSE), Clinical Dementia Rating Scale Sum Boxes (CDR-SB), Disease Assessment Scale-Cognitive (ADAS-Cog), Cooperative Study-Activities Daily Living (ADCS-ADL) from baseline until time observation. Statistical analysis conducted using Stata 14 RevMan 5.4. purpose data processing, including generating network evidence plots, surface under cumulative ranking curve (SUCRA) ranking, league funnel visually summarize evaluate relative effectiveness publication bias multiple interventions. Mean differences (MD) 95% confidence interval (95%CI) effect sizes analyze continuous variables. Results This encompassed six RCTs involving 2,193 patients. Semorinemab more effective than placebo MMSE ADAS-Cog scores (MDs ranging between 0.52 3.21; MDs 0.17 3.30). Placebo showed relatively good according SUCRA CDR-SB ADCS-ADL (75.7 79.5%). Tilavonemab exhibited similar that two indicators. lower incidence AE, SAE, fall, urinary tract infections placebo, statistically significant. Most results no statistical difference. Conclusion indicated antibodies, such promise terms managing AD. Further studies are needed confirm these findings, assess long-term effects, refine treatment protocols. Systematic review registration https://www.crd.york.ac.uk/prospero/#myprospero , CRD42024583388.
Language: Английский
Citations
2
Addiction, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 13, 2025
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related
Language: Английский
Citations
2
American Journal of Obstetrics and Gynecology, Journal Year: 2022, Volume and Issue: 227(4), P. 571 - 581
Published: May 31, 2022
Language: Английский
Citations
66
Addictive Behaviors, Journal Year: 2025, Volume and Issue: 163, P. 108242 - 108242
Published: Jan. 2, 2025
Language: Английский
Citations
1
Addiction, Journal Year: 2022, Volume and Issue: 117(10), P. 2591 - 2601
Published: Feb. 23, 2022
There have been few head-to-head clinical trials of pharmacotherapies for alcohol withdrawal (AW). We, therefore, aimed to evaluate the comparative performance AW.Six databases were searched randomized through November 2021. Trials included after a blinded review by two independent reviewers. Outcomes incident seizures, delirium tremens, AW severity scores, adverse events, dropouts, dropouts from length hospital stay, use additional medications, total benzodiazepine requirements, and death. Effect sizes pooled using frequentist random-effects network meta-analysis models generate summary ORs Cohen's d standardized mean differences (SMDs).Across 149 trials, there 10 692 participants (76% male, median 43.5 years old). spanned mild (n = 32), moderate 51), severe 66). Fixed-schedule chlormethiazole (OR, 0.16; 95% CI, 0.04-0.65), fixed-schedule diazepam 0.04-0.59), lorazepam (OR 0.19; 0.08-0.45), chlordiazepoxide 0.21; 0.08-0.53), divalproex 0.22; 0.05-0.86) superior placebo at reducing seizures. However, only 0.05-0.76) reduced tremens. Oxcarbazepine (d -3.69; -6.21 -1.17), carbamazepine -2.76; -4.13 -1.40), oxazepam -2.55; -4.26 -0.83), γ-hydroxybutyrate -1.80; -3.35 -0.26) improved endpoint Clinical Institute Withdrawal Assessment Alcohol-Revised scores over placebo. Promazine agents significantly associated with greater because events. The quality evidence was downgraded substantial risk bias, heterogeneity, inconsistency, imprecision.Although some pharmacotherapeutic modalities, particularly benzodiazepines, appear be safe efficacious measures withdrawal, methodological issues high bias prevent consistent estimate their performance.
Language: Английский
Citations
23
Journal of Eating Disorders, Journal Year: 2021, Volume and Issue: 9(1)
Published: Dec. 1, 2021
Abstract Aim Individuals with anorexia nervosa (AN) often present substance use and disorders (SUDs). However, the prevalence of SUDs in AN has not been studied in-depth, especially differences between types [e.g., AN-R (restrictive type) AN-BP (binge-eating/purge type]. Therefore, this systematic review meta-analysis aimed to assess samples. Method Systematic database searches peer-reviewed literature were conducted following online databases: MEDLINE, PsycINFO, Embase, CINAHL from inception January 2021. We restricted eligibility research studies reporting for either or individuals AN. Random-effects meta-analyses using Freeman–Tukey double arcsine transformations performed on eligible estimate pooled proportions 95% confidence intervals (CIs). Results Fifty-two met inclusion criteria, including 14,695 identified as having (mean age: 22.82 years). Random estimates showed that had a 16% those (AN-BP = 18% vs. 7%). Drug abuse/dependence 7% 9% 5%). In looked at specific disorders, there was 10% alcohol 15% 3%) 6% cannabis 4% 0%). addition, terms use, 37% caffeine 29% 25% tobacco 14% Conclusion This is most comprehensive comorbid persons AN, an overall 16%. Comorbid SUDs, drugs, alcohol, cannabis, all more common compared throughout. clinicians should be aware high SUD comorbidity Finally, consider screening integrating treatments target Plain English Summary may also have disorder Thus, we determine examined published reported found drug These rates much higher binge-eating/purging type restrictive many low Nonetheless,
Language: Английский
Citations
31
Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 5, 2025
Language: Английский
Citations
0
Frontiers in Psychiatry, Journal Year: 2025, Volume and Issue: 16
Published: March 21, 2025
Substance Use Disorders (SUDs) pose a significant public health challenge. Medications used for treatment of SUDs are limited in their efficacy, particularly cannabis and stimulant use disorders, non-pharmacological interventions have shown, at most, moderate effectiveness, leaving continuing need improved treatments. Contingency management (CM) is an evidence-based with promising results, operationalized SUD programs by using monetary rewards to help patients achieve target behaviors such as abstinence. Several factors limit the viability CM sustainable, effective treatment, suggesting insufficiency reinforcement alone. Implementation can be costly, requiring increased reinforcers over time reach behaviors, effects do not endure. We propose integrative model that explicitly incorporates intrinsic into enhance its effectiveness. This involves redirecting salience attribution towards goals activities personally relevant motivating individual involve substance use. may address current challenges some barriers implementation clinical practice.
Language: Английский
Citations
0
Journal of Substance Use and Addiction Treatment, Journal Year: 2024, Volume and Issue: 167, P. 209486 - 209486
Published: Aug. 14, 2024
Language: Английский
Citations
3
Epigenomes, Journal Year: 2022, Volume and Issue: 6(3), P. 27 - 27
Published: Aug. 26, 2022
Cannabis is one of the most commonly used and abused illicit drugs in world today. The United States (US) currently has highest annual prevalence rate cannabis consumption world, 17.9% individuals aged 12 or older, it on rise. With increasing use comes potential for an increase abuse, according to Substance Abuse Mental Health Services Administration (SAMHSA), approximately 5.1% Americans had Use Disorder (CUD) 2020. Research shown that genetics epigenetics play a significant role CUD. In fact, 50–70% liability CUD 40–48% initiation have been found be result genetic factors. usage also linked increased risk psychiatric disorders Reward Deficiency Syndrome (RDS) subsets like schizophrenia, depression, anxiety, substance disorder. Comprehension epigenetic aspects cannabinoids necessary future research, treatment plans, production pure cannabinoid compounds, which will essential FDA approval. conclusion, having better understanding underpinnings use, CUD, endocannabinoid system as whole aid development effective FDA-approved therapies advancement personalized medicine.
Language: Английский
Citations
13